Vascular Biogenics Ltd. - Ordinary Shares (VBLT): Price and Financial Metrics


Vascular Biogenics Ltd. - Ordinary Shares (VBLT): $2.33

-0.06 (-2.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VBLT POWR Grades


  • VBLT scores best on the Sentiment dimension, with a Sentiment rank ahead of 71.14% of US stocks.
  • The strongest trend for VBLT is in Momentum, which has been heading down over the past 47 weeks.
  • VBLT ranks lowest in Momentum; there it ranks in the 4th percentile.

VBLT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for VBLT is 0.01 -- better than just 7.14% of US stocks.
  • Of note is the ratio of Vascular Biogenics Ltd's sales and general administrative expense to its total operating expenses; only 10.58% of US stocks have a lower such ratio.
  • With a price/sales ratio of 190.4, Vascular Biogenics Ltd has a higher such ratio than 97.88% of stocks in our set.
  • Stocks that are quantitatively similar to VBLT, based on their financial statements, market capitalization, and price volatility, are CBIO, AYLA, XCUR, PIRS, and ACIU.
  • VBLT's SEC filings can be seen here. And to visit Vascular Biogenics Ltd's official web site, go to www.vblrx.com.

VBLT Valuation Summary

  • VBLT's price/sales ratio is 186.4; this is 1542.29% higher than that of the median Healthcare stock.
  • VBLT's price/sales ratio has moved NA NA over the prior 84 months.
  • VBLT's EV/EBIT ratio has moved up 3.9 over the prior 84 months.

Below are key valuation metrics over time for VBLT.

Stock Date P/S P/B P/E EV/EBIT
VBLT 2021-08-31 186.4 2.6 -5.3 -4.2
VBLT 2021-08-30 170.4 2.4 -4.8 -3.7
VBLT 2021-08-27 166.5 2.4 -4.7 -3.6
VBLT 2021-08-26 161.0 2.3 -4.5 -3.5
VBLT 2021-08-25 160.2 2.3 -4.5 -3.5
VBLT 2021-08-24 161.0 2.3 -4.5 -3.5

VBLT Growth Metrics

  • The 5 year cash and equivalents growth rate now stands at 8.11%.
  • Its 4 year price growth rate is now at -63.75%.
  • Its 2 year revenue growth rate is now at -94.95%.
VBLT's revenue has moved down $13,537,000 over the prior 33 months.

The table below shows VBLT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 0.771 -22.289 -27.345
2021-03-31 0.741 -23.552 -25.155
2020-12-31 0.922 -23.378 -24.225
2020-09-30 0.843 -19.831 -22.697
2020-06-30 0.729 -19.999 -21.776
2020-03-31 0.709 -15.585 -20.628

VBLT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VBLT has a Quality Grade of C, ranking ahead of 41.64% of graded US stocks.
  • VBLT's asset turnover comes in at 0.015 -- ranking 378th of 677 Pharmaceutical Products stocks.
  • ISEE, SRNE, and CNCE are the stocks whose asset turnover ratios are most correlated with VBLT.

The table below shows VBLT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.015 0.403 -1.059
2021-03-31 0.016 0.418 -0.951
2020-12-31 0.020 0.573 -0.863
2020-09-30 0.018 0.724 -0.741
2020-06-30 0.015 0.742 -0.740
2020-03-31 0.014 0.749 -0.628

VBLT Price Target

For more insight on analysts targets of VBLT, see our VBLT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.70 Average Broker Recommendation 1.3 (Strong Buy)

VBLT Stock Price Chart Interactive Chart >

Price chart for VBLT

VBLT Price/Volume Stats

Current price $2.33 52-week high $3.17
Prev. close $2.39 52-week low $1.01
Day low $2.30 Volume 459,400
Day high $2.40 Avg. volume 701,355
50-day MA $2.25 Dividend yield N/A
200-day MA $2.16 Market Cap 145.32M

Vascular Biogenics Ltd. - Ordinary Shares (VBLT) Company Bio


Vascular Biogenics Limited is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. The company was founded in 2000 and is based in Or Yehuda, Israel.


VBLT Latest News Stream


Event/Time News Detail
Loading, please wait...

VBLT Latest Social Stream


Loading social stream, please wait...

View Full VBLT Social Stream

Latest VBLT News From Around the Web

Below are the latest news stories about Vascular Biogenics Ltd that investors may wish to consider to help them evaluate VBLT as an investment opportunity.

VBL Therapeutics to Present at Upcoming Conferences

TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd Annual Global Investment Conference Mon., Sept. 13, 2021Fireside chat available on-demand beginning at 7:00 a.m. ET Cell & Gene Therapy World Asia 2021 conferenceWed., Sept. 15, 2021Presentation Time: 4:45 PM (SGT)Keynote Presentation Topic: VB-111: Transformative Gene therapy with the Potential to Chang

Yahoo | September 10, 2021

VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility

U.S. FDA CMC clearance of VB-111 produced in Modiin, Israel facility an important milestone toward potential commercializationOVAL Phase 3 trial evaluating VB-111 in platinum resistant ovarian cancer has recruited nearly 80% of target enrollment; remains on track to complete enrollment in 1Q22OVAL PFS readout expected in 2H22 may support BLA submission TEL AVIV, Israel, Aug. 30, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced enrollment of new patients in VB-111 studies

Yahoo | August 30, 2021

We Think Vascular Biogenics (NASDAQ:VBLT) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | August 23, 2021

thoughts on these estimates, before EPS results? Vascular Biogenics (NASDAQ:VBLT)

Earnings results for Vascular Biogenics , Analyst Opinion on Vascular Biogenics , Earnings and Valuation of (NASDAQ:VBLT), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post thoughts on these estimates, before EPS results? Vascular Biogenics (NASDAQ:VBLT) appeared first on .

Stock Market Daily | August 16, 2021

Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -20.00% and -48.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 16, 2021

Read More 'VBLT' Stories Here

VBLT Price Returns

1-mo 17.68%
3-mo 4.48%
6-mo 19.49%
1-year 77.86%
3-year 45.63%
5-year -50.95%
YTD 23.28%
2020 57.50%
2019 23.71%
2018 -86.34%
2017 46.39%
2016 -7.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.874 seconds.